Skip to main content
Funded Studies

Vicki L. Nienaber, PhD

President and Chief Scientific Officer at Zenobia Therapeutics, Inc.

Location: San Diego, CA United States

Vicki Nienaber, PhD, is well known for her pioneering work in the field of drug discovery using fragment-based screening and structure-based drug design. At Zenobia, Dr. Nienaber is focused on applying these methods to identify compounds with the right properties to cross the blood-brain-barrier, a major obstacle in central nervous system drug discovery.

Dr. Nienaber was most recently chief scientific officer at ActiveSight, a division of Rigaku Americas Corporation, where she built a diverse team of protein biochemistry, X-ray crystallography and drug discovery experts. Before that, she was senior director of lead discovery and crystallography at SGX Pharmaceuticals, where she oversaw strategic drug discovery and structural biology alliances with Novartis and Eli Lilly and initiated their internal kinase lead discovery project. While at Abbott Laboratories, Dr. Nienaber was the lead inventor of crystallographic fragment-based screening, co-inventor of the ACTORTM robotic system for automated crystal sample handling and a leader in structure-based drug design methods.

Associated Grants

  • Identification of Small Molecules that Stabilize Parkin in an Active Conformation


  • Characterization of LRRK2 Inhibitors for Advanced Drug-like Properties


  • Discovery of LRRK2 Target Engagement Ligands to be Used in Imaging Studies


  • Discovery of Novel Inhibitors of LRRK2 for the Treatment of Parkinson's Disease


We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.